Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

What Was Tested

The paper reports a study of Cagrilintide and Amylin (Islet Amyloid Polypeptide), published as a randomized controlled trial.

Natural amylin is a pancreatic hormone that induces satiety.

Cagrilintide is a long-acting amylin analogue under investigation for weight management.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Eligible participants were adults aged at least 18 years without diabetes, with a body-mass index of at least 30 kg/m2 or at least 27 kg/m2 with hypertension or dyslipidaemia.

Participants and investigators were masked to the assigned study treatment with respect to active versus pooled placebo treatment, but not to different active treatments.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.

The participants were allocated by chance, so the Cagrilintide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Cagrilintide.

Some participants received a placebo instead of Cagrilintide, giving a reference point.

Running at several centres spread the Cagrilintide study over different clinics and patient groups.

The primary endpoint was the percentage change in bodyweight from baseline to week 26, assessed in all randomly assigned participants according to the trial product estimand (assuming all participants were adherent to treatment) and to the treatment policy estimand (regardless of adherence to treatment).

This trial is registered with ClinicalTrials.gov, NCT03856047, and is closed to new participants.

What Was Measured

The subject headings attached to it are Africa, Body Mass Index, Europe, Hypoglycemic Agents, Islet Amyloid Polypeptide, Liraglutide and North America.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cagrilintide and Amylin (Islet Amyloid Polypeptide).

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Lancet (London, England)), a journal based in England.

More context: the Cagrilintide compound page and the Amylin (Islet Amyloid Polypeptide) compound page.